The First New U.S. Sunscreen Active in 20 Years Opened a Narrow Door

What exactly is settled?

On June 10, 2026, through final administrative order OTC000039, the FDA amended 'Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use' to add bemotrizinol as a sunscreen active generally recognized as safe and effective (GRASE). The permitted concentration is up to 6%, for adults and children six months of age and older. The order took effect on August 9, 2026.

The process itself followed the announced sequence. The FDA issued a proposed order on December 12, 2025, accepted comments through January 26, 2026, and after reviewing them made no substantive changes between the proposed and final orders. The practically important part is the marketing requirement clarified alongside it: sunscreen products containing bemotrizinol may be marketed without submitting a new drug application (NDA), provided they fully comply with the monograph requirements.

What is settled here should be separated from what is not. The effective date is the point at which the ingredient may begin to be used in U.S. sunscreen formulations; it is not the point at which products reach shelves. Reporting puts the first products containing it on U.S. shelves somewhere between September and October, with the raw material supplied by dsm-firmenich under the name 'Parsol Shield' and an 18-month exclusivity on its U.S. sales. The volume or terms on which a Korean brand could actually secure the material are not confirmed in public sources, so supply has to be checked case by case.

1. A monograph listing is a specification, not an approval

The first misreading to clear up is 'it has been approved, so we can now sell our sunscreen in the U.S.' Adding an ingredient to the monograph means that using it within the set concentration and conditions allows sale as an OTC drug without separate review. Put the other way, the NDA exemption applies only when the monograph requirements are fully met.

One ingredient opening does not automatically clear an entire formula. The concentration ceiling, the other filters it may be combined with, and the testing and labeling requirements all have to fall inside the frame the monograph sets. The key point is that having this ingredient in a formula you already use in Korea does not by itself make U.S. sale possible.

If you are considering U.S. suncare, the order of checks starts with the regime, not the ingredient. In Korea sunscreen is a functional cosmetic, while in the U.S. it is regulated as an over-the-counter drug, and Korean coverage repeatedly notes that entering the U.S. market means redesigning the product to OTC rules and going through FDA procedures.

• Whether this product will be redesigned to U.S. OTC drug specification
• Whether the current filter combination falls within the U.S. monograph
• Who rewrites the labeling to OTC standards, and on what schedule
• How much of the Korean functional-cosmetic dossier can be reused

2. The 18-month exclusivity is the real schedule variable

The most practical constraint in this case is not regulation but raw material. Reporting states that dsm-firmenich holds an 18-month exclusivity on U.S. sales of bemotrizinol, a period beginning when the first consumer product becomes commercially available. That the ingredient is open and that you can buy the quantity you want when you want it are different propositions.

Large companies are already moving. Kenvue, owner of Neutrogena and Aveeno, is reported to have confirmed it will include bemotrizinol in its sunscreen pipeline after the FDA effective date. Where early volumes are allocated may shift when later entrants can move.

The useful action at this stage is therefore not to tear up a formula in advance but to ask about supply terms. Confirming with your manufacturing partner when the material can be secured, the minimum purchase conditions, and whether it can be applied to U.S.-bound production separates the prepared from the unprepared when the exclusivity period ends.

3. The strengths here are UVA coverage and photostability

Bemotrizinol draws attention because it offers a level of UVA protection U.S. consumers have had little access to. Reporting describes it as a stable non-mineral option that does not break down in sunlight, unlike avobenzone. It is a broad-spectrum filter already long used in Europe, Asia and Australia.

Korean coverage cites strong photostability for longer-lasting protection, low skin absorption for reduced irritation, and a lighter feel with less white cast than conventional U.S. sunscreens. It also notes that these characteristics line up with the lightweight, low-white-cast sensory profile that has won K-beauty suncare a following in North America.

That said, such descriptions concern the general characteristics of the ingredient; they are not evidence for any particular product's performance. Actual SPF and UVA figures are determined by the full formula, application amount and test conditions. Before putting an ingredient name at the center of marketing copy, confirm that finished-product test results support the claim.

4. A Korean functional-cosmetic dossier does not transfer as is

A brand that has developed sunscreen in Korea already holds a functional-cosmetic review dossier. The problem is that its premises differ. Korea runs functional review inside the cosmetic regime; the U.S. runs monograph compliance inside the drug regime. Different regimes mean different required tests and different labeling formats.

In practice the faster route is to list what has to be redone first. If the formula is redesigned for the U.S., specifications diverge from the domestic product, so the decision of one product for both markets or separate products has to come first. Delay that decision and containers, cartons, barcodes and production lines all move underneath you later.

It is also more efficient to bring the question forward in discussions with an OEM/ODM partner such as COSLAB. 'What would we have to rebuild if this formula moved to U.S. OTC specification?' moves the schedule far more than 'Can you handle U.S. export?'

5. What to decide now is sequence, not formula

Rewriting a formula immediately because one ingredient was added is moving too fast. The effective date has passed, but the first products are only now reaching shelves and the exclusivity period is only now beginning. The way to get ahead in this phase is to settle the order of decisions rather than to change the formula.

The sequence generally runs like this: decide whether the U.S. is a principal market, then confirm the gap between the current formula and OTC specification, and on that basis align raw-material availability with your partner. Secure the material first and choose the market afterwards, and you have bought inventory you may not be able to use.

This change also concerns one market. The ingredient was already in use in Europe and Asia, so for a brand already selling there this is less a new opportunity than one fewer barrier to U.S. entry. Working out which of the two describes your situation is the starting point for the decision.

The first question for the brief

Write this on the first line of the brief: if we take our suncare to the U.S., does it go as the same formula as the domestic product or as a separate specification? Bemotrizinol joining the monograph means the ingredient options grew by one, not that the U.S. entry process got shorter. To move when the 18-month exclusivity lifts, the work to do now is not ordering material but documenting the gap between U.S. OTC specification and your own formula.